Please assess the completion status of the following clinical trial:

Trial Title: Sensoril(Ashwaganhda)for Bipolar Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* DSMIV-TR diagnosis of Bipolar Disorder~* Ages 18 to 65~* Men or Women~* 8th grade education or greater~* Able to provide competent written informed consent~* Current main mood stabilizer and mood status (YMRS and MADRS scores less than or equal to 10) are stable for greater than or equal to 4 weeks by history.~Exclusion Criteria:~* Medically unstable conditions~* Known allergy to Sensoril® (or Ashwagandha)~* Current cognitive decline is attributable to a diagnosis of dementia or other neurological disorder~* Pregnant or lactating women~* Mini-mental score (MMSE) less than or equal to 23~* Currently receiving donepezil, rivastigamine, or galatamine, or memantine or any marketed agent for slowing memory loss in dementia~* Abnormal clinical thyroid status~* Currently (or within past 2 weeks) receiving St. John's Wort, Gingko or Omega-3

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1- Sensoril (Ashwagandha) (Type: EXPERIMENTAL): Sensoril (Ashwagandha) will be administered using random assignment at a dose of 250 mg/day, increasing to a dose of 500 mg/day by the second week.
- 2 - Placebo (Type: PLACEBO_COMPARATOR): Placebo will be administered using random assignment at a dose of 250 mg/day, increasing to a dose of 500 mg/day by the second week.

Based on this trial design, predict the completion outcome and termination type (if applicable).